The plaintiffs say the company should have warned them earlier about problems with its variable universal life policies.

Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December ...

Bitcoin, the world’s largest cryptocurrency, continued its downward trend on Thursday, touching its lowest level since ...

Thanks to Donald Trump’s support and Joe Biden’s failure to intervene, private equity is inching ever closer to tapping into ...